nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—CYP3A7—Ifosfamide—testicular cancer	0.0716	0.177	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0716	0.177	CbGbCtD
Aripiprazole—CYP3A5—Ifosfamide—testicular cancer	0.0537	0.133	CbGbCtD
Aripiprazole—ADRA1B—vas deferens—testicular cancer	0.0396	0.28	CbGeAlD
Aripiprazole—ABCB1—Dactinomycin—testicular cancer	0.0296	0.0733	CbGbCtD
Aripiprazole—CYP3A5—Etoposide—testicular cancer	0.0257	0.0635	CbGbCtD
Aripiprazole—HTR7—vas deferens—testicular cancer	0.023	0.163	CbGeAlD
Aripiprazole—CYP3A4—Ifosfamide—testicular cancer	0.021	0.0519	CbGbCtD
Aripiprazole—ABCB1—Vinblastine—testicular cancer	0.0186	0.0459	CbGbCtD
Aripiprazole—CYP2D6—Vinblastine—testicular cancer	0.0175	0.0433	CbGbCtD
Aripiprazole—ABCB1—Cisplatin—testicular cancer	0.017	0.0421	CbGbCtD
Aripiprazole—ABCB1—Etoposide—testicular cancer	0.0167	0.0414	CbGbCtD
Aripiprazole—H1F0—semen—testicular cancer	0.0133	0.0943	CbGeAlD
Aripiprazole—ABCB1—Doxorubicin—testicular cancer	0.0114	0.0282	CbGbCtD
Aripiprazole—CYP3A4—Vinblastine—testicular cancer	0.0111	0.0275	CbGbCtD
Aripiprazole—ABCB1—Methotrexate—testicular cancer	0.011	0.0273	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—testicular cancer	0.0107	0.0266	CbGbCtD
Aripiprazole—CYP3A4—Etoposide—testicular cancer	0.01	0.0248	CbGbCtD
Aripiprazole—HTR7—vein—testicular cancer	0.00979	0.0694	CbGeAlD
Aripiprazole—CYP3A4—Doxorubicin—testicular cancer	0.00683	0.0169	CbGbCtD
Aripiprazole—HTR2A—vein—testicular cancer	0.00611	0.0433	CbGeAlD
Aripiprazole—H1F0—embryo—testicular cancer	0.003	0.0213	CbGeAlD
Aripiprazole—DRD4—testis—testicular cancer	0.00288	0.0204	CbGeAlD
Aripiprazole—H1F0—seminal vesicle—testicular cancer	0.00282	0.02	CbGeAlD
Aripiprazole—HTR1E—female gonad—testicular cancer	0.0028	0.0199	CbGeAlD
Aripiprazole—CHRM4—testis—testicular cancer	0.00218	0.0154	CbGeAlD
Aripiprazole—DRD5—female gonad—testicular cancer	0.00214	0.0152	CbGeAlD
Aripiprazole—H1F0—gonad—testicular cancer	0.00204	0.0144	CbGeAlD
Aripiprazole—H1F0—female gonad—testicular cancer	0.00166	0.0117	CbGeAlD
Aripiprazole—KCNH2—seminal vesicle—testicular cancer	0.00162	0.0115	CbGeAlD
Aripiprazole—ADRA2C—seminal vesicle—testicular cancer	0.0016	0.0113	CbGeAlD
Aripiprazole—H1F0—testis—testicular cancer	0.00147	0.0104	CbGeAlD
Aripiprazole—ADRA2A—seminal vesicle—testicular cancer	0.00128	0.00904	CbGeAlD
Aripiprazole—HTR7—gonad—testicular cancer	0.00126	0.00891	CbGeAlD
Aripiprazole—HTR2A—embryo—testicular cancer	0.00116	0.00819	CbGeAlD
Aripiprazole—CHRM3—female gonad—testicular cancer	0.00107	0.00761	CbGeAlD
Aripiprazole—H1F0—lymph node—testicular cancer	0.00107	0.00754	CbGeAlD
Aripiprazole—CHRM3—testis—testicular cancer	0.000953	0.00675	CbGeAlD
Aripiprazole—KCNH2—female gonad—testicular cancer	0.000952	0.00675	CbGeAlD
Aripiprazole—ADRA2C—female gonad—testicular cancer	0.00094	0.00666	CbGeAlD
Aripiprazole—ADRA2A—gonad—testicular cancer	0.000923	0.00654	CbGeAlD
Aripiprazole—HTR7—testis—testicular cancer	0.000907	0.00642	CbGeAlD
Aripiprazole—DRD2—testis—testicular cancer	0.000857	0.00607	CbGeAlD
Aripiprazole—KCNH2—testis—testicular cancer	0.000845	0.00598	CbGeAlD
Aripiprazole—ADRA2C—testis—testicular cancer	0.000833	0.0059	CbGeAlD
Aripiprazole—CYP3A5—female gonad—testicular cancer	0.000786	0.00557	CbGeAlD
Aripiprazole—HTR2A—gonad—testicular cancer	0.000784	0.00556	CbGeAlD
Aripiprazole—HTR2B—lymph node—testicular cancer	0.000767	0.00544	CbGeAlD
Aripiprazole—HRH1—female gonad—testicular cancer	0.000763	0.00541	CbGeAlD
Aripiprazole—ABCB1—embryo—testicular cancer	0.000757	0.00536	CbGeAlD
Aripiprazole—ADRA2A—female gonad—testicular cancer	0.00075	0.00531	CbGeAlD
Aripiprazole—ABCB1—seminal vesicle—testicular cancer	0.000711	0.00504	CbGeAlD
Aripiprazole—HRH1—testis—testicular cancer	0.000677	0.0048	CbGeAlD
Aripiprazole—ADRA2A—testis—testicular cancer	0.000665	0.00471	CbGeAlD
Aripiprazole—KCNH2—lymph node—testicular cancer	0.000612	0.00434	CbGeAlD
Aripiprazole—ADRA2C—lymph node—testicular cancer	0.000604	0.00428	CbGeAlD
Aripiprazole—CYP2D6—female gonad—testicular cancer	0.000581	0.00411	CbGeAlD
Aripiprazole—HTR2A—testis—testicular cancer	0.000565	0.00401	CbGeAlD
Aripiprazole—CYP2D6—testis—testicular cancer	0.000515	0.00365	CbGeAlD
Aripiprazole—ABCB1—gonad—testicular cancer	0.000514	0.00364	CbGeAlD
Aripiprazole—HRH1—lymph node—testicular cancer	0.000491	0.00348	CbGeAlD
Aripiprazole—ADRA2A—lymph node—testicular cancer	0.000482	0.00341	CbGeAlD
Aripiprazole—ABCB1—female gonad—testicular cancer	0.000418	0.00296	CbGeAlD
Aripiprazole—ABCB1—testis—testicular cancer	0.000371	0.00262	CbGeAlD
Aripiprazole—ABCB1—lymph node—testicular cancer	0.000269	0.0019	CbGeAlD
Aripiprazole—Pharyngitis—Epirubicin—testicular cancer	0.000126	0.000291	CcSEcCtD
Aripiprazole—Cardiac disorder—Methotrexate—testicular cancer	0.000126	0.00029	CcSEcCtD
Aripiprazole—Sweating—Doxorubicin—testicular cancer	0.000126	0.000289	CcSEcCtD
Aripiprazole—Urinary tract disorder—Epirubicin—testicular cancer	0.000126	0.000289	CcSEcCtD
Aripiprazole—Oedema peripheral—Epirubicin—testicular cancer	0.000126	0.000289	CcSEcCtD
Aripiprazole—Haematuria—Doxorubicin—testicular cancer	0.000125	0.000288	CcSEcCtD
Aripiprazole—Connective tissue disorder—Epirubicin—testicular cancer	0.000125	0.000288	CcSEcCtD
Aripiprazole—Urethral disorder—Epirubicin—testicular cancer	0.000125	0.000287	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000124	0.000286	CcSEcCtD
Aripiprazole—Epistaxis—Doxorubicin—testicular cancer	0.000124	0.000285	CcSEcCtD
Aripiprazole—Angiopathy—Methotrexate—testicular cancer	0.000124	0.000284	CcSEcCtD
Aripiprazole—Sinusitis—Doxorubicin—testicular cancer	0.000123	0.000283	CcSEcCtD
Aripiprazole—Immune system disorder—Methotrexate—testicular cancer	0.000123	0.000283	CcSEcCtD
Aripiprazole—Visual impairment—Epirubicin—testicular cancer	0.000123	0.000282	CcSEcCtD
Aripiprazole—Mediastinal disorder—Methotrexate—testicular cancer	0.000123	0.000282	CcSEcCtD
Aripiprazole—Agranulocytosis—Doxorubicin—testicular cancer	0.000123	0.000282	CcSEcCtD
Aripiprazole—Chills—Methotrexate—testicular cancer	0.000122	0.000281	CcSEcCtD
Aripiprazole—Nausea—Ifosfamide—testicular cancer	0.000121	0.000279	CcSEcCtD
Aripiprazole—Diarrhoea—Cisplatin—testicular cancer	0.000121	0.000277	CcSEcCtD
Aripiprazole—Alopecia—Methotrexate—testicular cancer	0.00012	0.000277	CcSEcCtD
Aripiprazole—Bradycardia—Doxorubicin—testicular cancer	0.00012	0.000276	CcSEcCtD
Aripiprazole—Mental disorder—Methotrexate—testicular cancer	0.000119	0.000274	CcSEcCtD
Aripiprazole—Eye disorder—Epirubicin—testicular cancer	0.000119	0.000274	CcSEcCtD
Aripiprazole—Hypersensitivity—Etoposide—testicular cancer	0.000119	0.000274	CcSEcCtD
Aripiprazole—Tinnitus—Epirubicin—testicular cancer	0.000119	0.000273	CcSEcCtD
Aripiprazole—Malnutrition—Methotrexate—testicular cancer	0.000119	0.000272	CcSEcCtD
Aripiprazole—Erythema—Methotrexate—testicular cancer	0.000119	0.000272	CcSEcCtD
Aripiprazole—Haemoglobin—Doxorubicin—testicular cancer	0.000118	0.000272	CcSEcCtD
Aripiprazole—Flushing—Epirubicin—testicular cancer	0.000118	0.000272	CcSEcCtD
Aripiprazole—Cardiac disorder—Epirubicin—testicular cancer	0.000118	0.000272	CcSEcCtD
Aripiprazole—Rhinitis—Doxorubicin—testicular cancer	0.000118	0.000272	CcSEcCtD
Aripiprazole—Haemorrhage—Doxorubicin—testicular cancer	0.000118	0.000271	CcSEcCtD
Aripiprazole—Hepatitis—Doxorubicin—testicular cancer	0.000118	0.000271	CcSEcCtD
Aripiprazole—Hypoaesthesia—Doxorubicin—testicular cancer	0.000117	0.00027	CcSEcCtD
Aripiprazole—Pharyngitis—Doxorubicin—testicular cancer	0.000117	0.000269	CcSEcCtD
Aripiprazole—Urinary tract disorder—Doxorubicin—testicular cancer	0.000116	0.000268	CcSEcCtD
Aripiprazole—Oedema peripheral—Doxorubicin—testicular cancer	0.000116	0.000267	CcSEcCtD
Aripiprazole—Dysgeusia—Methotrexate—testicular cancer	0.000116	0.000267	CcSEcCtD
Aripiprazole—Asthenia—Etoposide—testicular cancer	0.000116	0.000266	CcSEcCtD
Aripiprazole—Connective tissue disorder—Doxorubicin—testicular cancer	0.000116	0.000266	CcSEcCtD
Aripiprazole—HTR2C—GPCR ligand binding—INSL3—testicular cancer	0.000116	0.00587	CbGpPWpGaD
Aripiprazole—Angiopathy—Epirubicin—testicular cancer	0.000116	0.000266	CcSEcCtD
Aripiprazole—Urethral disorder—Doxorubicin—testicular cancer	0.000116	0.000266	CcSEcCtD
Aripiprazole—DRD5—GPCR downstream signaling—INSL3—testicular cancer	0.000115	0.00584	CbGpPWpGaD
Aripiprazole—Immune system disorder—Epirubicin—testicular cancer	0.000115	0.000265	CcSEcCtD
Aripiprazole—Mediastinal disorder—Epirubicin—testicular cancer	0.000115	0.000264	CcSEcCtD
Aripiprazole—Back pain—Methotrexate—testicular cancer	0.000115	0.000264	CcSEcCtD
Aripiprazole—Chills—Epirubicin—testicular cancer	0.000114	0.000263	CcSEcCtD
Aripiprazole—Pruritus—Etoposide—testicular cancer	0.000114	0.000263	CcSEcCtD
Aripiprazole—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	0.000114	0.00576	CbGpPWpGaD
Aripiprazole—Visual impairment—Doxorubicin—testicular cancer	0.000114	0.000261	CcSEcCtD
Aripiprazole—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	0.000113	0.00571	CbGpPWpGaD
Aripiprazole—Alopecia—Epirubicin—testicular cancer	0.000113	0.000259	CcSEcCtD
Aripiprazole—Vomiting—Cisplatin—testicular cancer	0.000112	0.000258	CcSEcCtD
Aripiprazole—Vision blurred—Methotrexate—testicular cancer	0.000112	0.000257	CcSEcCtD
Aripiprazole—Mental disorder—Epirubicin—testicular cancer	0.000112	0.000257	CcSEcCtD
Aripiprazole—Rash—Cisplatin—testicular cancer	0.000111	0.000255	CcSEcCtD
Aripiprazole—Dermatitis—Cisplatin—testicular cancer	0.000111	0.000255	CcSEcCtD
Aripiprazole—Malnutrition—Epirubicin—testicular cancer	0.000111	0.000255	CcSEcCtD
Aripiprazole—Erythema—Epirubicin—testicular cancer	0.000111	0.000255	CcSEcCtD
Aripiprazole—ADRA1B—GPCR ligand binding—INSL3—testicular cancer	0.000111	0.00562	CbGpPWpGaD
Aripiprazole—Diarrhoea—Etoposide—testicular cancer	0.00011	0.000254	CcSEcCtD
Aripiprazole—Eye disorder—Doxorubicin—testicular cancer	0.00011	0.000253	CcSEcCtD
Aripiprazole—Ill-defined disorder—Methotrexate—testicular cancer	0.00011	0.000253	CcSEcCtD
Aripiprazole—Tinnitus—Doxorubicin—testicular cancer	0.00011	0.000253	CcSEcCtD
Aripiprazole—Anaemia—Methotrexate—testicular cancer	0.00011	0.000252	CcSEcCtD
Aripiprazole—Cardiac disorder—Doxorubicin—testicular cancer	0.000109	0.000252	CcSEcCtD
Aripiprazole—Flushing—Doxorubicin—testicular cancer	0.000109	0.000252	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—testicular cancer	0.000109	0.000251	CcSEcCtD
Aripiprazole—Tension—Epirubicin—testicular cancer	0.000109	0.00025	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—testicular cancer	0.000109	0.00025	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—testicular cancer	0.000108	0.000248	CcSEcCtD
Aripiprazole—CYP3A7—Biological oxidations—HPGDS—testicular cancer	0.000108	0.00546	CbGpPWpGaD
Aripiprazole—Back pain—Epirubicin—testicular cancer	0.000107	0.000247	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—testicular cancer	0.000107	0.000246	CcSEcCtD
Aripiprazole—Malaise—Methotrexate—testicular cancer	0.000107	0.000246	CcSEcCtD
Aripiprazole—Dizziness—Etoposide—testicular cancer	0.000107	0.000245	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—testicular cancer	0.000107	0.000245	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—testicular cancer	0.000106	0.000245	CcSEcCtD
Aripiprazole—Vertigo—Methotrexate—testicular cancer	0.000106	0.000245	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—testicular cancer	0.000106	0.000244	CcSEcCtD
Aripiprazole—Leukopenia—Methotrexate—testicular cancer	0.000106	0.000244	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—testicular cancer	0.000106	0.000243	CcSEcCtD
Aripiprazole—Nausea—Cisplatin—testicular cancer	0.000105	0.000241	CcSEcCtD
Aripiprazole—DRD5—Signaling by GPCR—INSL3—testicular cancer	0.000105	0.0053	CbGpPWpGaD
Aripiprazole—Vision blurred—Epirubicin—testicular cancer	0.000105	0.00024	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—testicular cancer	0.000104	0.000239	CcSEcCtD
Aripiprazole—Cough—Methotrexate—testicular cancer	0.000103	0.000238	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—testicular cancer	0.000103	0.000237	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—testicular cancer	0.000103	0.000237	CcSEcCtD
Aripiprazole—Convulsion—Methotrexate—testicular cancer	0.000103	0.000236	CcSEcCtD
Aripiprazole—Vomiting—Etoposide—testicular cancer	0.000103	0.000236	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—testicular cancer	0.000103	0.000236	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—testicular cancer	0.000103	0.000236	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—testicular cancer	0.000103	0.000236	CcSEcCtD
Aripiprazole—DRD2—GPCR ligand binding—INSL3—testicular cancer	0.000102	0.00518	CbGpPWpGaD
Aripiprazole—Agitation—Epirubicin—testicular cancer	0.000102	0.000234	CcSEcCtD
Aripiprazole—Rash—Etoposide—testicular cancer	0.000102	0.000234	CcSEcCtD
Aripiprazole—Dermatitis—Etoposide—testicular cancer	0.000102	0.000234	CcSEcCtD
Aripiprazole—Headache—Etoposide—testicular cancer	0.000101	0.000233	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—testicular cancer	0.000101	0.000232	CcSEcCtD
Aripiprazole—Chest pain—Methotrexate—testicular cancer	0.000101	0.000232	CcSEcCtD
Aripiprazole—Arthralgia—Methotrexate—testicular cancer	0.000101	0.000232	CcSEcCtD
Aripiprazole—Myalgia—Methotrexate—testicular cancer	0.000101	0.000232	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—testicular cancer	0.000101	0.000232	CcSEcCtD
Aripiprazole—CHRM3—Integration of energy metabolism—STK11—testicular cancer	0.000101	0.0051	CbGpPWpGaD
Aripiprazole—HTR2A—GPCR ligand binding—INSL3—testicular cancer	0.000101	0.0051	CbGpPWpGaD
Aripiprazole—Dysgeusia—Doxorubicin—testicular cancer	0.0001	0.000231	CcSEcCtD
Aripiprazole—HRH1—GPCR ligand binding—INSL3—testicular cancer	0.0001	0.00509	CbGpPWpGaD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.0001	0.00023	CcSEcCtD
Aripiprazole—CHRM1—GPCR ligand binding—INSL3—testicular cancer	0.0001	0.00507	CbGpPWpGaD
Aripiprazole—Malaise—Epirubicin—testicular cancer	0.0001	0.00023	CcSEcCtD
Aripiprazole—CHRM3—GPCR ligand binding—INSL3—testicular cancer	9.97e-05	0.00505	CbGpPWpGaD
Aripiprazole—Discomfort—Methotrexate—testicular cancer	9.97e-05	0.000229	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—testicular cancer	9.97e-05	0.000229	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—testicular cancer	9.96e-05	0.000229	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—testicular cancer	9.95e-05	0.000229	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—testicular cancer	9.93e-05	0.000228	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—testicular cancer	9.93e-05	0.000228	CcSEcCtD
Aripiprazole—CHRM2—GPCR ligand binding—INSL3—testicular cancer	9.87e-05	0.005	CbGpPWpGaD
Aripiprazole—Muscle spasms—Doxorubicin—testicular cancer	9.87e-05	0.000227	CcSEcCtD
Aripiprazole—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	9.85e-05	0.00499	CbGpPWpGaD
Aripiprazole—Palpitations—Epirubicin—testicular cancer	9.8e-05	0.000225	CcSEcCtD
Aripiprazole—Confusional state—Methotrexate—testicular cancer	9.75e-05	0.000224	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—testicular cancer	9.75e-05	0.000224	CcSEcCtD
Aripiprazole—Cough—Epirubicin—testicular cancer	9.68e-05	0.000222	CcSEcCtD
Aripiprazole—Anaphylactic shock—Methotrexate—testicular cancer	9.67e-05	0.000222	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—testicular cancer	9.67e-05	0.000222	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—testicular cancer	9.61e-05	0.000221	CcSEcCtD
Aripiprazole—Infection—Methotrexate—testicular cancer	9.61e-05	0.000221	CcSEcCtD
Aripiprazole—Nausea—Etoposide—testicular cancer	9.59e-05	0.000221	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—testicular cancer	9.58e-05	0.00022	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—testicular cancer	9.52e-05	0.000219	CcSEcCtD
Aripiprazole—Nervous system disorder—Methotrexate—testicular cancer	9.49e-05	0.000218	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—testicular cancer	9.49e-05	0.000218	CcSEcCtD
Aripiprazole—Thrombocytopenia—Methotrexate—testicular cancer	9.47e-05	0.000218	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—testicular cancer	9.44e-05	0.000217	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—testicular cancer	9.44e-05	0.000217	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—testicular cancer	9.44e-05	0.000217	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—testicular cancer	9.43e-05	0.000217	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—testicular cancer	9.41e-05	0.000216	CcSEcCtD
Aripiprazole—Skin disorder—Methotrexate—testicular cancer	9.4e-05	0.000216	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	9.38e-05	0.000216	CcSEcCtD
Aripiprazole—Hyperhidrosis—Methotrexate—testicular cancer	9.35e-05	0.000215	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—testicular cancer	9.33e-05	0.000214	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—testicular cancer	9.25e-05	0.000213	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—testicular cancer	9.23e-05	0.000212	CcSEcCtD
Aripiprazole—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	9.23e-05	0.00468	CbGpPWpGaD
Aripiprazole—ADRA1B—LPA receptor mediated events—MMP2—testicular cancer	9.23e-05	0.00468	CbGpPWpGaD
Aripiprazole—Vertigo—Doxorubicin—testicular cancer	9.22e-05	0.000212	CcSEcCtD
Aripiprazole—Anorexia—Methotrexate—testicular cancer	9.22e-05	0.000212	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—testicular cancer	9.2e-05	0.000212	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—testicular cancer	9.19e-05	0.000211	CcSEcCtD
Aripiprazole—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	9.15e-05	0.00464	CbGpPWpGaD
Aripiprazole—Confusional state—Epirubicin—testicular cancer	9.13e-05	0.00021	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—testicular cancer	9.07e-05	0.000208	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—testicular cancer	9.05e-05	0.000208	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—testicular cancer	9.05e-05	0.000208	CcSEcCtD
Aripiprazole—Hypotension—Methotrexate—testicular cancer	9.04e-05	0.000208	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—testicular cancer	9.02e-05	0.000207	CcSEcCtD
Aripiprazole—Infection—Epirubicin—testicular cancer	8.99e-05	0.000207	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—testicular cancer	8.96e-05	0.000206	CcSEcCtD
Aripiprazole—Shock—Epirubicin—testicular cancer	8.91e-05	0.000205	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—testicular cancer	8.89e-05	0.000204	CcSEcCtD
Aripiprazole—HTR6—GPCR downstream signaling—INSL3—testicular cancer	8.89e-05	0.0045	CbGpPWpGaD
Aripiprazole—HTR7—GPCR downstream signaling—INSL3—testicular cancer	8.88e-05	0.0045	CbGpPWpGaD
Aripiprazole—Nervous system disorder—Epirubicin—testicular cancer	8.88e-05	0.000204	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—testicular cancer	8.86e-05	0.000204	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—testicular cancer	8.86e-05	0.000204	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—testicular cancer	8.83e-05	0.000203	CcSEcCtD
Aripiprazole—HTR1D—GPCR downstream signaling—INSL3—testicular cancer	8.82e-05	0.00447	CbGpPWpGaD
Aripiprazole—Musculoskeletal discomfort—Methotrexate—testicular cancer	8.81e-05	0.000203	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—testicular cancer	8.79e-05	0.000202	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—testicular cancer	8.75e-05	0.000201	CcSEcCtD
Aripiprazole—Insomnia—Methotrexate—testicular cancer	8.75e-05	0.000201	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—testicular cancer	8.74e-05	0.000201	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—testicular cancer	8.74e-05	0.000201	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—testicular cancer	8.74e-05	0.000201	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—testicular cancer	8.71e-05	0.0002	CcSEcCtD
Aripiprazole—Paraesthesia—Methotrexate—testicular cancer	8.69e-05	0.0002	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	8.68e-05	0.000199	CcSEcCtD
Aripiprazole—HTR1B—GPCR downstream signaling—INSL3—testicular cancer	8.64e-05	0.00438	CbGpPWpGaD
Aripiprazole—Discomfort—Doxorubicin—testicular cancer	8.63e-05	0.000198	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—testicular cancer	8.63e-05	0.000198	CcSEcCtD
Aripiprazole—Dyspnoea—Methotrexate—testicular cancer	8.62e-05	0.000198	CcSEcCtD
Aripiprazole—Somnolence—Methotrexate—testicular cancer	8.6e-05	0.000198	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—testicular cancer	8.54e-05	0.000196	CcSEcCtD
Aripiprazole—Dyspepsia—Methotrexate—testicular cancer	8.51e-05	0.000196	CcSEcCtD
Aripiprazole—DRD4—GPCR downstream signaling—INSL3—testicular cancer	8.5e-05	0.00431	CbGpPWpGaD
Aripiprazole—Hypotension—Epirubicin—testicular cancer	8.46e-05	0.000194	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—testicular cancer	8.45e-05	0.000194	CcSEcCtD
Aripiprazole—Decreased appetite—Methotrexate—testicular cancer	8.41e-05	0.000193	CcSEcCtD
Aripiprazole—CHRM4—GPCR downstream signaling—INSL3—testicular cancer	8.38e-05	0.00425	CbGpPWpGaD
Aripiprazole—Oedema—Doxorubicin—testicular cancer	8.38e-05	0.000193	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—testicular cancer	8.38e-05	0.000193	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Methotrexate—testicular cancer	8.35e-05	0.000192	CcSEcCtD
Aripiprazole—Fatigue—Methotrexate—testicular cancer	8.34e-05	0.000192	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—testicular cancer	8.32e-05	0.000191	CcSEcCtD
Aripiprazole—Pain—Methotrexate—testicular cancer	8.27e-05	0.00019	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—testicular cancer	8.25e-05	0.00019	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—testicular cancer	8.24e-05	0.000189	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—testicular cancer	8.21e-05	0.000189	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—testicular cancer	8.2e-05	0.000189	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—testicular cancer	8.19e-05	0.000188	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—testicular cancer	8.17e-05	0.000188	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—testicular cancer	8.14e-05	0.000187	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—testicular cancer	8.13e-05	0.000187	CcSEcCtD
Aripiprazole—HTR2B—GPCR downstream signaling—INSL3—testicular cancer	8.11e-05	0.00411	CbGpPWpGaD
Aripiprazole—Hyperhidrosis—Doxorubicin—testicular cancer	8.1e-05	0.000186	CcSEcCtD
Aripiprazole—HTR6—Signaling by GPCR—INSL3—testicular cancer	8.07e-05	0.00409	CbGpPWpGaD
Aripiprazole—Dyspnoea—Epirubicin—testicular cancer	8.07e-05	0.000186	CcSEcCtD
Aripiprazole—HTR7—Signaling by GPCR—INSL3—testicular cancer	8.06e-05	0.00409	CbGpPWpGaD
Aripiprazole—Somnolence—Epirubicin—testicular cancer	8.05e-05	0.000185	CcSEcCtD
Aripiprazole—CHRM5—GPCR downstream signaling—INSL3—testicular cancer	8.03e-05	0.00407	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling by GPCR—INSL3—testicular cancer	8.01e-05	0.00406	CbGpPWpGaD
Aripiprazole—Anorexia—Doxorubicin—testicular cancer	7.98e-05	0.000184	CcSEcCtD
Aripiprazole—Feeling abnormal—Methotrexate—testicular cancer	7.97e-05	0.000183	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—testicular cancer	7.97e-05	0.000183	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Methotrexate—testicular cancer	7.91e-05	0.000182	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—testicular cancer	7.87e-05	0.000181	CcSEcCtD
Aripiprazole—HTR1B—Signaling by GPCR—INSL3—testicular cancer	7.84e-05	0.00397	CbGpPWpGaD
Aripiprazole—Hypotension—Doxorubicin—testicular cancer	7.83e-05	0.00018	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—testicular cancer	7.81e-05	0.00018	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—testicular cancer	7.8e-05	0.000179	CcSEcCtD
Aripiprazole—CYP3A5—Biological oxidations—HPGDS—testicular cancer	7.79e-05	0.00395	CbGpPWpGaD
Aripiprazole—Pain—Epirubicin—testicular cancer	7.74e-05	0.000178	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—testicular cancer	7.74e-05	0.000178	CcSEcCtD
Aripiprazole—CHRM4—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	7.72e-05	0.00391	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—INSL3—testicular cancer	7.72e-05	0.00391	CbGpPWpGaD
Aripiprazole—Urticaria—Methotrexate—testicular cancer	7.68e-05	0.000177	CcSEcCtD
Aripiprazole—DRD1—GPCR downstream signaling—INSL3—testicular cancer	7.65e-05	0.00388	CbGpPWpGaD
Aripiprazole—Abdominal pain—Methotrexate—testicular cancer	7.65e-05	0.000176	CcSEcCtD
Aripiprazole—Body temperature increased—Methotrexate—testicular cancer	7.65e-05	0.000176	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—testicular cancer	7.63e-05	0.000175	CcSEcCtD
Aripiprazole—CHRM4—Signaling by GPCR—INSL3—testicular cancer	7.61e-05	0.00386	CbGpPWpGaD
Aripiprazole—Insomnia—Doxorubicin—testicular cancer	7.58e-05	0.000174	CcSEcCtD
Aripiprazole—DRD3—GPCR downstream signaling—INSL3—testicular cancer	7.55e-05	0.00383	CbGpPWpGaD
Aripiprazole—Paraesthesia—Doxorubicin—testicular cancer	7.52e-05	0.000173	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—testicular cancer	7.47e-05	0.000172	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—testicular cancer	7.46e-05	0.000171	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—testicular cancer	7.45e-05	0.000171	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—testicular cancer	7.4e-05	0.00017	CcSEcCtD
Aripiprazole—CHRM5—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	7.39e-05	0.00375	CbGpPWpGaD
Aripiprazole—Dyspepsia—Doxorubicin—testicular cancer	7.37e-05	0.000169	CcSEcCtD
Aripiprazole—HTR2B—Signaling by GPCR—INSL3—testicular cancer	7.37e-05	0.00373	CbGpPWpGaD
Aripiprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	7.36e-05	0.00373	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—INSL3—testicular cancer	7.29e-05	0.00369	CbGpPWpGaD
Aripiprazole—Decreased appetite—Doxorubicin—testicular cancer	7.28e-05	0.000167	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—testicular cancer	7.23e-05	0.000166	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—testicular cancer	7.22e-05	0.000166	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—testicular cancer	7.19e-05	0.000165	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—testicular cancer	7.16e-05	0.000165	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—testicular cancer	7.16e-05	0.000165	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—testicular cancer	7.16e-05	0.000165	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—testicular cancer	7.16e-05	0.000165	CcSEcCtD
Aripiprazole—Hypersensitivity—Methotrexate—testicular cancer	7.13e-05	0.000164	CcSEcCtD
Aripiprazole—HTR1E—Signaling Pathways—INSL3—testicular cancer	6.98e-05	0.00354	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—INSL3—testicular cancer	6.95e-05	0.00352	CbGpPWpGaD
Aripiprazole—Asthenia—Methotrexate—testicular cancer	6.94e-05	0.00016	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—testicular cancer	6.9e-05	0.000159	CcSEcCtD
Aripiprazole—ADRB1—GPCR downstream signaling—INSL3—testicular cancer	6.88e-05	0.00349	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—INSL3—testicular cancer	6.86e-05	0.00347	CbGpPWpGaD
Aripiprazole—Gastrointestinal pain—Doxorubicin—testicular cancer	6.85e-05	0.000157	CcSEcCtD
Aripiprazole—Pruritus—Methotrexate—testicular cancer	6.84e-05	0.000157	CcSEcCtD
Aripiprazole—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	6.82e-05	0.00345	CbGpPWpGaD
Aripiprazole—Hypersensitivity—Epirubicin—testicular cancer	6.67e-05	0.000153	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—testicular cancer	6.65e-05	0.000153	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—testicular cancer	6.62e-05	0.000152	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—testicular cancer	6.62e-05	0.000152	CcSEcCtD
Aripiprazole—Diarrhoea—Methotrexate—testicular cancer	6.62e-05	0.000152	CcSEcCtD
Aripiprazole—HTR1A—GPCR downstream signaling—INSL3—testicular cancer	6.58e-05	0.00333	CbGpPWpGaD
Aripiprazole—HTR2C—GPCR downstream signaling—INSL3—testicular cancer	6.55e-05	0.00332	CbGpPWpGaD
Aripiprazole—Asthenia—Epirubicin—testicular cancer	6.49e-05	0.000149	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—testicular cancer	6.4e-05	0.000147	CcSEcCtD
Aripiprazole—Dizziness—Methotrexate—testicular cancer	6.4e-05	0.000147	CcSEcCtD
Aripiprazole—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	6.37e-05	0.00323	CbGpPWpGaD
Aripiprazole—ADRA1B—GPCR downstream signaling—INSL3—testicular cancer	6.27e-05	0.00318	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—INSL3—testicular cancer	6.25e-05	0.00317	CbGpPWpGaD
Aripiprazole—Diarrhoea—Epirubicin—testicular cancer	6.19e-05	0.000142	CcSEcCtD
Aripiprazole—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	6.19e-05	0.00314	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—INSL3—testicular cancer	6.18e-05	0.00313	CbGpPWpGaD
Aripiprazole—Hypersensitivity—Doxorubicin—testicular cancer	6.17e-05	0.000142	CcSEcCtD
Aripiprazole—Vomiting—Methotrexate—testicular cancer	6.15e-05	0.000141	CcSEcCtD
Aripiprazole—Rash—Methotrexate—testicular cancer	6.1e-05	0.00014	CcSEcCtD
Aripiprazole—Dermatitis—Methotrexate—testicular cancer	6.09e-05	0.00014	CcSEcCtD
Aripiprazole—Headache—Methotrexate—testicular cancer	6.06e-05	0.000139	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—testicular cancer	6.01e-05	0.000138	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—testicular cancer	5.99e-05	0.000138	CcSEcCtD
Aripiprazole—HTR1A—Signaling by GPCR—INSL3—testicular cancer	5.97e-05	0.00303	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—INSL3—testicular cancer	5.94e-05	0.00301	CbGpPWpGaD
Aripiprazole—Pruritus—Doxorubicin—testicular cancer	5.93e-05	0.000136	CcSEcCtD
Aripiprazole—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.91e-05	0.003	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	5.78e-05	0.00293	CbGpPWpGaD
Aripiprazole—DRD2—GPCR downstream signaling—INSL3—testicular cancer	5.78e-05	0.00293	CbGpPWpGaD
Aripiprazole—Vomiting—Epirubicin—testicular cancer	5.76e-05	0.000132	CcSEcCtD
Aripiprazole—Nausea—Methotrexate—testicular cancer	5.75e-05	0.000132	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—testicular cancer	5.73e-05	0.000132	CcSEcCtD
Aripiprazole—Rash—Epirubicin—testicular cancer	5.71e-05	0.000131	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—testicular cancer	5.7e-05	0.000131	CcSEcCtD
Aripiprazole—ADRA1B—Signaling by GPCR—INSL3—testicular cancer	5.69e-05	0.00288	CbGpPWpGaD
Aripiprazole—HTR2A—GPCR downstream signaling—INSL3—testicular cancer	5.68e-05	0.00288	CbGpPWpGaD
Aripiprazole—HRH1—GPCR downstream signaling—INSL3—testicular cancer	5.67e-05	0.00287	CbGpPWpGaD
Aripiprazole—Headache—Epirubicin—testicular cancer	5.67e-05	0.00013	CcSEcCtD
Aripiprazole—CHRM1—GPCR downstream signaling—INSL3—testicular cancer	5.65e-05	0.00286	CbGpPWpGaD
Aripiprazole—CHRM3—GPCR downstream signaling—INSL3—testicular cancer	5.64e-05	0.00286	CbGpPWpGaD
Aripiprazole—CHRM2—GPCR downstream signaling—INSL3—testicular cancer	5.58e-05	0.00283	CbGpPWpGaD
Aripiprazole—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	5.57e-05	0.00282	CbGpPWpGaD
Aripiprazole—Dizziness—Doxorubicin—testicular cancer	5.54e-05	0.000127	CcSEcCtD
Aripiprazole—CYP2D6—Biological oxidations—HPGDS—testicular cancer	5.54e-05	0.00281	CbGpPWpGaD
Aripiprazole—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	5.4e-05	0.00274	CbGpPWpGaD
Aripiprazole—Nausea—Epirubicin—testicular cancer	5.38e-05	0.000124	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—testicular cancer	5.33e-05	0.000122	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—testicular cancer	5.28e-05	0.000121	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—testicular cancer	5.28e-05	0.000121	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—testicular cancer	5.25e-05	0.000121	CcSEcCtD
Aripiprazole—DRD2—Signaling by GPCR—INSL3—testicular cancer	5.25e-05	0.00266	CbGpPWpGaD
Aripiprazole—CHRM1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	5.21e-05	0.00264	CbGpPWpGaD
Aripiprazole—CHRM3—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	5.19e-05	0.00263	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	5.17e-05	0.00262	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—INSL3—testicular cancer	5.16e-05	0.00262	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—INSL3—testicular cancer	5.15e-05	0.00261	CbGpPWpGaD
Aripiprazole—CHRM2—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	5.14e-05	0.0026	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—INSL3—testicular cancer	5.13e-05	0.0026	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—INSL3—testicular cancer	5.12e-05	0.00259	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—INSL3—testicular cancer	5.07e-05	0.00257	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	5.05e-05	0.00256	CbGpPWpGaD
Aripiprazole—Nausea—Doxorubicin—testicular cancer	4.97e-05	0.000114	CcSEcCtD
Aripiprazole—HTR6—Signaling Pathways—INSL3—testicular cancer	4.77e-05	0.00242	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—INSL3—testicular cancer	4.76e-05	0.00241	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—INSL3—testicular cancer	4.73e-05	0.0024	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	4.7e-05	0.00238	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—INSL3—testicular cancer	4.63e-05	0.00235	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—INSL3—testicular cancer	4.56e-05	0.00231	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—INSL3—testicular cancer	4.5e-05	0.00228	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—INSL3—testicular cancer	4.35e-05	0.00221	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—INSL3—testicular cancer	4.31e-05	0.00218	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—INSL3—testicular cancer	4.1e-05	0.00208	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—INSL3—testicular cancer	4.05e-05	0.00205	CbGpPWpGaD
Aripiprazole—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	3.93e-05	0.00199	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—INSL3—testicular cancer	3.69e-05	0.00187	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—INSL3—testicular cancer	3.66e-05	0.00185	CbGpPWpGaD
Aripiprazole—CYP3A4—Biological oxidations—HPGDS—testicular cancer	3.62e-05	0.00183	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—INSL3—testicular cancer	3.53e-05	0.00179	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—INSL3—testicular cancer	3.51e-05	0.00178	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—INSL3—testicular cancer	3.42e-05	0.00173	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—INSL3—testicular cancer	3.36e-05	0.0017	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—INSL3—testicular cancer	3.1e-05	0.00157	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—INSL3—testicular cancer	3.05e-05	0.00155	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—INSL3—testicular cancer	3.04e-05	0.00154	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—INSL3—testicular cancer	3.03e-05	0.00154	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—INSL3—testicular cancer	3.02e-05	0.00153	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—INSL3—testicular cancer	2.99e-05	0.00152	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—INSL3—testicular cancer	2.99e-05	0.00151	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—INSL3—testicular cancer	2.77e-05	0.00141	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—H2AFZ—testicular cancer	2.23e-05	0.00113	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—STK11—testicular cancer	2.22e-05	0.00113	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—KITLG—testicular cancer	2.06e-05	0.00104	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—H2AFZ—testicular cancer	1.98e-05	0.001	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—STK11—testicular cancer	1.97e-05	0.000996	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—HPGDS—testicular cancer	1.84e-05	0.000934	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—KITLG—testicular cancer	1.82e-05	0.000922	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—HPGDS—testicular cancer	1.79e-05	0.000907	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—HPGDS—testicular cancer	1.58e-05	0.000803	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—FGFR3—testicular cancer	1.53e-05	0.000774	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—H2AFZ—testicular cancer	1.53e-05	0.000773	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—H2AFZ—testicular cancer	1.52e-05	0.000773	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—STK11—testicular cancer	1.52e-05	0.000769	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—STK11—testicular cancer	1.52e-05	0.000768	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—H2AFZ—testicular cancer	1.51e-05	0.000768	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—STK11—testicular cancer	1.51e-05	0.000763	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—H2AFZ—testicular cancer	1.48e-05	0.000752	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—STK11—testicular cancer	1.47e-05	0.000747	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—H2AFZ—testicular cancer	1.46e-05	0.00074	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—HPGDS—testicular cancer	1.45e-05	0.000736	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—STK11—testicular cancer	1.45e-05	0.000735	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—H2AFZ—testicular cancer	1.44e-05	0.00073	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—STK11—testicular cancer	1.43e-05	0.000725	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—KITLG—testicular cancer	1.4e-05	0.000712	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—KIT—testicular cancer	1.4e-05	0.000711	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—KITLG—testicular cancer	1.4e-05	0.000711	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—KITLG—testicular cancer	1.39e-05	0.000706	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—H2AFZ—testicular cancer	1.39e-05	0.000706	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—STK11—testicular cancer	1.39e-05	0.000702	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—H2AFZ—testicular cancer	1.38e-05	0.000699	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—STK11—testicular cancer	1.37e-05	0.000695	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—KITLG—testicular cancer	1.36e-05	0.000691	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—FGFR3—testicular cancer	1.35e-05	0.000685	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—KITLG—testicular cancer	1.34e-05	0.00068	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—STK11—testicular cancer	1.34e-05	0.000678	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—HPGDS—testicular cancer	1.33e-05	0.000675	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—KITLG—testicular cancer	1.32e-05	0.000671	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—H2AFZ—testicular cancer	1.31e-05	0.000666	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—STK11—testicular cancer	1.31e-05	0.000662	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—STK11—testicular cancer	1.3e-05	0.000659	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—H2AFZ—testicular cancer	1.3e-05	0.000657	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—STK11—testicular cancer	1.29e-05	0.000653	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—KITLG—testicular cancer	1.28e-05	0.000649	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—KITLG—testicular cancer	1.27e-05	0.000643	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—KIT—testicular cancer	1.24e-05	0.000629	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—KITLG—testicular cancer	1.21e-05	0.000612	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—KITLG—testicular cancer	1.19e-05	0.000604	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—H2AFZ—testicular cancer	1.18e-05	0.000599	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—STK11—testicular cancer	1.17e-05	0.000595	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	1.17e-05	0.000593	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—STK11—testicular cancer	1.16e-05	0.00059	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—STK11—testicular cancer	1.15e-05	0.000583	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	1.13e-05	0.000573	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	1.12e-05	0.00057	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—STK11—testicular cancer	1.12e-05	0.000569	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—STK11—testicular cancer	1.12e-05	0.000566	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	1.09e-05	0.000554	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—STK11—testicular cancer	1.09e-05	0.000551	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KITLG—testicular cancer	1.09e-05	0.000551	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KITLG—testicular cancer	1.08e-05	0.000546	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—H2AFZ—testicular cancer	1.08e-05	0.000545	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—STK11—testicular cancer	1.07e-05	0.000542	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—STK11—testicular cancer	1.06e-05	0.000535	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—FGFR3—testicular cancer	1.04e-05	0.000529	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—FGFR3—testicular cancer	1.04e-05	0.000528	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KITLG—testicular cancer	1.04e-05	0.000527	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—FGFR3—testicular cancer	1.04e-05	0.000525	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KITLG—testicular cancer	1.03e-05	0.000524	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—FGFR3—testicular cancer	1.01e-05	0.000514	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KITLG—testicular cancer	1.01e-05	0.00051	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—HPGDS—testicular cancer	1e-05	0.000509	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—FGFR3—testicular cancer	9.98e-06	0.000506	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—H2AFZ—testicular cancer	9.92e-06	0.000503	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KITLG—testicular cancer	9.9e-06	0.000502	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—STK11—testicular cancer	9.86e-06	0.0005	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—FGFR3—testicular cancer	9.84e-06	0.000499	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	9.76e-06	0.000495	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—H2AFZ—testicular cancer	9.74e-06	0.000494	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—H2AFZ—testicular cancer	9.71e-06	0.000492	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—STK11—testicular cancer	9.7e-06	0.000492	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—STK11—testicular cancer	9.68e-06	0.000491	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—H2AFZ—testicular cancer	9.68e-06	0.00049	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—STK11—testicular cancer	9.68e-06	0.00049	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—STK11—testicular cancer	9.65e-06	0.000489	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—STK11—testicular cancer	9.62e-06	0.000488	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—H2AFZ—testicular cancer	9.58e-06	0.000486	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—KIT—testicular cancer	9.58e-06	0.000486	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—KIT—testicular cancer	9.57e-06	0.000485	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	9.56e-06	0.000484	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—STK11—testicular cancer	9.53e-06	0.000483	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—FGFR3—testicular cancer	9.53e-06	0.000483	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—KIT—testicular cancer	9.51e-06	0.000482	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—STK11—testicular cancer	9.5e-06	0.000482	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—HPGDS—testicular cancer	9.47e-06	0.00048	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—FGFR3—testicular cancer	9.43e-06	0.000478	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—KIT—testicular cancer	9.31e-06	0.000472	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—KIT—testicular cancer	9.16e-06	0.000464	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KITLG—testicular cancer	9.13e-06	0.000462	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—KIT—testicular cancer	9.04e-06	0.000458	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—FGFR3—testicular cancer	8.98e-06	0.000455	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KITLG—testicular cancer	8.98e-06	0.000455	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KITLG—testicular cancer	8.96e-06	0.000454	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KITLG—testicular cancer	8.93e-06	0.000453	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KITLG—testicular cancer	8.9e-06	0.000451	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	8.88e-06	0.00045	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—FGFR3—testicular cancer	8.86e-06	0.000449	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—STK11—testicular cancer	8.83e-06	0.000447	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KITLG—testicular cancer	8.82e-06	0.000447	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KITLG—testicular cancer	8.79e-06	0.000446	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—KIT—testicular cancer	8.75e-06	0.000443	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—KIT—testicular cancer	8.65e-06	0.000439	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—KIT—testicular cancer	8.25e-06	0.000418	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KITLG—testicular cancer	8.17e-06	0.000414	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—KIT—testicular cancer	8.14e-06	0.000412	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—FGFR3—testicular cancer	8.08e-06	0.000409	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	8e-06	0.000405	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—FGFR3—testicular cancer	7.72e-06	0.000391	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—FGFR3—testicular cancer	7.68e-06	0.000389	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	7.47e-06	0.000379	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KIT—testicular cancer	7.41e-06	0.000376	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—FGFR3—testicular cancer	7.36e-06	0.000373	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KIT—testicular cancer	7.35e-06	0.000372	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—STK11—testicular cancer	7.3e-06	0.00037	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KIT—testicular cancer	7.09e-06	0.000359	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KIT—testicular cancer	7.06e-06	0.000358	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—STK11—testicular cancer	6.88e-06	0.000349	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KIT—testicular cancer	6.86e-06	0.000348	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—FGFR3—testicular cancer	6.78e-06	0.000344	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KIT—testicular cancer	6.75e-06	0.000342	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—FGFR3—testicular cancer	6.67e-06	0.000338	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—FGFR3—testicular cancer	6.66e-06	0.000337	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—FGFR3—testicular cancer	6.64e-06	0.000336	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—FGFR3—testicular cancer	6.62e-06	0.000335	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—FGFR3—testicular cancer	6.55e-06	0.000332	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	6.53e-06	0.000331	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KIT—testicular cancer	6.23e-06	0.000316	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—HPGDS—testicular cancer	6.19e-06	0.000314	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KIT—testicular cancer	6.13e-06	0.00031	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KIT—testicular cancer	6.11e-06	0.00031	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KIT—testicular cancer	6.09e-06	0.000309	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KIT—testicular cancer	6.07e-06	0.000308	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	6.07e-06	0.000308	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KIT—testicular cancer	6.02e-06	0.000305	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KIT—testicular cancer	6e-06	0.000304	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KIT—testicular cancer	5.57e-06	0.000282	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—STK11—testicular cancer	4.5e-06	0.000228	CbGpPWpGaD
